ProfileGDS5678 / 1420620_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 93% 92% 94% 95% 92% 95% 94% 93% 93% 93% 93% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8447693
GSM967853U87-EV human glioblastoma xenograft - Control 27.8960293
GSM967854U87-EV human glioblastoma xenograft - Control 38.0107493
GSM967855U87-EV human glioblastoma xenograft - Control 47.866592
GSM967856U87-EV human glioblastoma xenograft - Control 58.2189294
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.2346895
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3200192
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2595
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2032594
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8820593
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.8259593
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9350893
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0023993
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9998794